Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar

Sandoz and Regeneron Reach Agreement on Aflibercept Biosimilar Patent Disputes

Sandoz announced it has reached an agreement with Regeneron to resolve all outstanding US patent disputes related to the company’s aflibercept biosimilar, Enzeevu. The legal proceedings originated in August 2024, when Regeneron filed a patent infringement lawsuit against Sandoz in the US District Court for the District of New Jersey. The claims, made under the Biologics Price Competition and Innovation Act (BPCIA), asserted infringement of up to…

Regeneron patent deal with Sandoz clears path for new Eylea biosimilar launch in 2026

Sandoz can sell its biosimilar version of Regeneron’s Eylea in the US by the end of 2026, following a patent settlement between the two companies. The generic drugmaker announced Tuesday that ...

Sandoz and Regeneron reach agreement over biosimilar dispute

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar

Save (0) Please login to bookmarkClose Username or Email Address Password Remember Me Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea. Subscribe to Lawyerly to access this article.Already a subscriber? Username or Email Address Password Remember Me Lost your password? The post Regeneron, Bayer lose bid to block Sandoz …